Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.73 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.73 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinuclidinyl Benzilate SCHEMBL241173 | 0.86 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Quinuclidinyl Benzilate SCHEMBL59698 | 0.86 | CHRM2 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Quinuclidinyl Benzilate SCHEMBL29433215 | 0.84 | CHRM2 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL17978654 | 0.84 | CHRM2 (0.82) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL17978655 | 0.84 | CHRM2 (0.82) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL29631412 | 0.84 | CHRM2 (0.82) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL17978653 | 0.84 | CHRM2 (0.82) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL18016223 | 0.84 | CHRM2 (0.82) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL17985842 | 0.84 | CHRM2 (0.82) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL18016260 | 0.83 | CHRM2 (0.80) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | claimed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | claimed |
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.